anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a medical healthcare instrument for the cervical vertebra. The medical healthcare instrument comprises a neck ring body, a buffer mat layer is arranged on the inner side face of the neck ring, concave cavities are formed in the neck ring, and vibrators are arranged in the concave cavities. Vibration rods are arranged on the vibrator, vibration balls is arranged at the ends of the vibration rods, the vibration rods penetrate through the buffer mat layer, a supporting rod with the shape matched with that of the afterbrain is arranged at the top of the neck ring, and a sliding groove is formed in the side wall of the supporting rod. A rolling shaft is arranged in the sliding groove, massage rubber columns are arranged on the rolling shaft, rubber massage balls are arranged at the ends of the massage rubber columns, and a massage motor is arranged at the bottom of the sliding groove. An eccentric wheel is arranged on a spindle of the massage motor, a transmission belt is arranged between the eccentric wheel and the rolling shaft, a pin shaft and a stress spring are arranged at the joint of the supporting rod and the neck ring, and the pin shaft penetrates through the stress spring and abuts against the afterbrain of the human body under the action of the stress spring. The medical healthcare instrument is simple in structure, convenient to operate, good in use stability, high in applicability and good in practicality.
PURPOSE:A pharmaceutical for nasotracheal administration obtained by blending a physiologically active substance having immunological regulating action with a surfactant having a steroid skeleton or triterpene skeleton and having improved absorption through nasal mucosae. CONSTITUTION:A pharmaceutical for nasotracheal administration containing a surfactant, e.g. saponin or bile acid salt, having a steroid skeleton or triterpenoid skeleton in a physiologically active substance, e.g. interferon, having immunological regulating action. The administration method for the physiologically active substance having immunological regulating action is limited to an injection, but the administration by injection is inconvenient involving pain. Although nasotracheal administration is considered as the administration method other than the injection, addition of the surfactant to the physiologically active substance provides rapid absorption of the active substance through the nasal mucosae. For example, an aqueous solution is specifically sprayed into the nasal cavity, but the pharmaceutical may be formed into a freezedried powder from the viewpoint of the preservation stability and dissolved in use. The content of the surfactant is 0.01-50wt/vol% in an aqueous solution or suspension.
PURPOSE: This study aimed to reveal the association between the osteoporosis self-assessment tool for Asians (OSTA) and airflow limitation (AL) in post-menopausal Japanese women.
PARTICIPANTS AND METHODS: This cross-sectional study included 1580 participants undergoing a comprehensive health examination using spirometry and dual-energy X-ray absorptiometry. The OSTA was calculated by subtracting the age in years from the body weight (BW) in kilograms, and the result was multiplied by 0.2. The OSTA risk level was defined as low (>-1), moderate (-4 to -1), or high (<-4). AL was defined as forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) <0.7. The association between the OSTA and AL was assessed using logistic regression analysis.
RESULTS: The prevalence of AL was significantly higher in the high OSTA group (15.3%) than in the low OSTA group (3.1%) (p<0.001). In multiple linear regression analysis, the OSTA was independently associated with FEV1/FVC. In logistic regression models adjusted for smoking status, alcohol consumption, current use of medication for diabetes, hyperglycemia, rheumatoid arthritis, second-hand smoke, and ovary removal showed a significantly higher risk of AL (odds ratio: 5.48; 95% confidence interval: 2.90-10.37; p<0.001) in participants with OSTA high risk than in those with OSTA low risk.
CONCLUSION: These results suggest that the OSTA high risk indicates reduced BMD at the femoral neck and presence of AL in Japanese post-menopausal women aged ≥45 years.
This is a double-blind, randomized controlled trial at an urban pediatric emergency department. Sample size (162) was based on a threshold equivalence of 7% (α = 0.05, power = 80%). Inclusion criteria were: non-toxic, immunocompetent, 3 months to 18 years old, English-speaking patients with clinical or ultrasound identified skin abscesses who were not on antibiotics. Patients were block randomized to receive placebo or trimethoprim/sulfamethoxazole following incision and drainage. Follow-up was a call at 2-3 days \& a repeat visit or call at 10-14 days. Treatment failure was defined as: persistent erythema, tenderness, and/or draining lesions. New lesion was defined as: primary resolution with development of new lesion (furuncle, carbuncle or abscess) at a different location. Compliance was evaluated by the return of the study medication or by patient report.
Abacavir and lamivudine are recommended antiretroviral medications used in the treatment of human immunodeficiency virus (HIV) infection in the United States and globally. Both agents are nucleos(t)ide reverse transcriptase inhibitors (NRTIs), which exert their antiviral activity following entry into target cells and phosphorylation by intracellular kinases to their active anabolites, carbovir-triphosphate (CBV-TP) and lamivudine-triphosphate (3TC-TP). There is limited knowledge regarding the pharmacokinetic (PK) disposition of abacavir and lamivudine anabolites in red blood cells (RBCs), neutrophils, and platelets. Abacavir has also been linked with prothrombotic activity and an increased risk of cardiovascular events in patients on this therapy, central theories of which point towards interference with purinergic signaling due to its structural similarity to endogenous adenosine and guanosine. These findings have not been replicated with other NRTI medications, such as tenofovir. This pilot study will characterize the pharmacokinetics (PK) of these medications in different cell types of persons living with HIV (PLWH) on these therapies as part of clinical care, and will examine endogenous nucleotide levels and metabolic profiles through the use of metabolomics in platelets specifically to better understand what changes might be happening within this cell type with the use of these medications.
A device 2 for administering a test substance such as an allergen 10 to the skin. The device has a first layer 4 and a second layer 6 with at least one protrusion 8, for containing the substance 10. There is a third layer 12 comprising an aperture 14. The protrusion of the second layer is located within the aperture. The device has a fourth layer 16 covering the aperture. There is a skin-piercing component 18 disposed within or above the aperture of the third layer and between the second and fourth layers. The skin piercing element may be biased towards a rest configuration and deformed when a force is applied. The skin piecing element may have a dome shaped base 20. There is also a method of manufacturing the device using alignment holes 44.
The invention relates to application of tetrahydrocurcumin in preparing an antidepressant and a method for preparing a solid dispersion of the tetrahydrocurcumin. The invention aims to provide the application of the tetrahydrocurcumin to prepare the antidepressant. The tetrahydrocurcumin and a surfactant are mixed in certain proportion to obtain the solid dispersion of the tetrahydrocurcumin. The method for preparing the solid dispersion of the tetrahydrocurcumin comprises the following steps that: according to the weight ratio of 1:3-1:30, the tetrahydrocurcumin and the surfactant are heated until completely melted, frozen in a low-temperature environment, and taken out, dried and crushed to obtain the solid dispersion of the tetrahydrocurcumin. The tetrahydrocurcumin and the solid dispersion of the tetrahydrocurcumin are used for preparing drugs, health care products, foods or food additives of relieving mental depression. The tetrahydrocurcumin has the function of relieving mental depression, and the function of the tetrahydrocurcumin is possibly related with the influence on a monoamine neurotransmitter system; moreover, compared with fluoxetine, the tetrahydrocurcumin has the advantages of low toxicity and good curing effect.
Anemia in chronic kidney disease (CKD) occurs due to insufficient production of erythropoietin to compensate for the decrease in hemoglobin. Anemia in CKD has traditionally been treated with periodic injections of erythropoiesis-stimulating agents (ESAs), which are recombinant human erythropoietin preparations. Although ESA improved anemia in CKD and dramatically improved the quality of life of patients, there are some patients who are hyporesponsive to ESA, and the use of large doses of ESA in these patients may have a negative impact on patient prognosis. Currently, HIF prolyl hydroxylase (HIF-PH) inhibitors have been approved in Japan as a new treatment for anemia in CKD. HIF-PH inhibitors activate HIF and promote the production of endogenous erythropoietin. The 2019 Nobel Prize in Physiology or Medicine was awarded for groundbreaking research that uncovered the HIF pathway. Because HIF-PH inhibitors improve both erythropoietin production and iron metabolism, they are expected to be effective in treating ESA hyporesponsiveness and solve the inconvenience of injectable preparations. On the other hand, its effects are systemic and multifaceted, and long-term effects must be closely monitored.
The invention discloses an application of miR-142-3p in treatment of high-salt-induced cardiac fibrosis, and relates to miR-142-3p related to high-salt-induced cardiac fibrosis, wherein a nucleotide sequence of miR-142-3p is shown in SEQ ID NO:1 and discloses application of an agonist of miR-142-3p in preparation of a medicament for treating high-salt induced cardiac fibrosis. The invention researches the action and mechanism of microRNA-142-3p in myocardial fibrosis induced by high salt. Fibrosis and mitophagy levels of NaCl-treated heart and NRCF increased and were alleviated by upregulation of miR-142-3 p. Fibrosis and mitophagy levels of NRCF increased after treatment with miR-142-3p anticoagulants. Expression of optic nerve protein (OPTN) in NRCF mitochondria was increased by NaCl and decreased by miR-142-3 p-agomiR. Down-regulation of OPTN inhibited NaCl-induced fibrosis, increasing autophagy of NRCF. These results miR-142-3p can reduce cardiac fibrosis by down-regulating OPTN, thereby reducing mitosis.
A compound of general formula (I) which is useful in treating hypocholesterolemia and atherosclerosis. In formula (I) X is oxygen or sulfur; R is hydrogen, alkyl having from 1 to 8 carbon atoms, or benzyl; R1? is phenyl, substituted phenyl, naphthyl, substituted naphthyl, an aralkyl group, a heterocyclic group, or a hydrocarbon chain of from 1 to 20 carbon atoms which is saturated or contains 1 to 3 double bonds and each of R2? and R3? is selected from hydrogen, provided both are not hydrogen, an aralkyl group, a hydrocarbon chain of from 1 to 20 carbon atoms which is saturated or contains 1 to 3 double bonds, a w-substituted alkyl C1-6?, a heterocyclic group, phenyl, substituted phenyl or NR2?R3? taken together form a monocyclic heterocyclic group.
Highly pathogenic strains of avian influenza (HPAI) devastate poultry flocks and result in significant economic losses for farmers due to high mortality, reduced egg production, and mandated euthanization of infected flocks. Within recent years, HPAI outbreaks have affected egg production flocks across the world. The H5N2 outbreak in the US in 2015 resulted in over 99% mortality. Here, we analyze sequence data from chickens that survived (42 cases) along with uninfected controls (28 samples) to find genomic regions that differ between these two groups and that, therefore, may encompass prime candidates that are resistant to HPAI. Blood samples were obtained from survivors of the 2015 HPAI outbreak plus age and genetics-matched non-affected controls. A whole-genome sequence was obtained, and genetic variants were characterized and used in a genome-wide association study to identify regions showing significant association with survival. Regions associated with HPAI resistance were observed on chromosomes 1, 2, 5, 8, 10, 11, 15, 20, and 28, with a number of candidate genes identified. We did not detect a specific locus which could fully explain the difference between survivors and controls. Influenza virus replication depends on multiple components of the host cellular machinery, with many genes involved in the host response.
Mobilization in the spine between ribs will be performed to increase the mobility of joints. To strengthen the muscles such as erector spinae, iliopsoas, and the quadratus lumborum, muscle activation will be done. Then the four exercises of the Schroth method which are the "50 x Swiss ball" exercise, Prone exercise, Sail exercise, and the Muscle-cylinder exercise will be performed. This will be followed by hot pack and static stretching of muscles.
PURPOSE:To provide an allergy-preventing fat or oil composition comprising a fat and oil containing a omega3 series fatty acid and a sesamin, not having adverse actions, having good safety and easily ingested. CONSTITUTION:A composition comprises a fat and oil containing at least one kind of alpha-linolenic acid, eicosapentaenic acid and docosahexaenic acid, e.g. perilla oil, linseed oil or a fish oil such as the oil of sardine, mackerel, bonito or tuna, and a sesame oil containing a sesamin. The compounding ratio of both the components comprises most practically 90-70wt.% of the perilla oil and 10-30wt.% of the sesame oil or 80-60wt.% of the perilla oil, 5-20wt.% of the fish oil and 10-30wt.% of the sesame oil. An omega3 series fatty acid/omega6 series fatty acid in a molar ratio of 4-2 as the fatty acids give an excellent allergy- preventing effect. The addition of a Ginkgo biloba extract, Scutellaria baicalensis extract, tea extract or Glycyrrhiza glabra gives a further higher effect, and permits to maintain the oxidation stability of the composition.
Over the past decade there were many studies over normal and pathological swallowing that discuss the influence of taste and temperature. Nevertheless there were many questions on the issue that remains to be solved, including the hemispheric lateralization of lesions dysphagic patients remains also to be fully understood.Swallowing disorder is defined as oropharyngeal dysphagia in presence of alterations in any phase of the complex swallowing dynamics. It could be congenital or acquired, affecting nutritional aspects, hydration, lung function and the individual's social integration \[1\]. Stroke, has a high incidence among neurological diseases, and cause disturbs on swallowing dynamics presenting signs of dysphagia in at least 50% of cases.A study that analyzed swallowing dynamics by videofluoroscopy in individuals with history of one or more stroke episodes with oropharyngeal dysphagia shows shorter pharyngeal and oropharyngeal transit times with cold stimulus than without them. Other study of heterogeneous neurological diseases such as cerebral palsy, brain trauma, stroke, and Alzheimer's disease, concluded that sour taste improved swallowing, minimizing laryngotracheal penetration and aspiration in individuals with neurological damaged. Chen et al. in an analysis of 42 healthy individuals with several taste bolus found that awareness and arousal could also influence the swallowing function.
Increases in serum transaminases (aspartate aminotransferase [AST]/serum glutamic-oxaloacetic transaminase, or alanine aminotransferase [ALT]/serum glutamic-pyruvic transaminase) have been reported with HMG-CoA reductase inhibitors, including LESCOL/LESCOL XL. In most cases, the elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy.

Approximately 1.1% of patients treated with LESCOL capsules in worldwide trials developed dose-related, persistent elevations of serum transaminase levels to more than 3 times the upper limit of normal. Fourteen of these patients (0.6%) were discontinued from therapy. In all clinical trials, a total of 33/2969 patients (1.1%) had persistent transaminase elevations with an average LESCOL exposure of approximately 71.2 weeks; 19 of these patients (0.6%) were discontinued. The majority of patients with these abnormal biochemical findings were asymptomatic.

In a pooled analysis of all placebo-controlled studies in which LESCOL capsules were used, persistent transaminase elevations (>3 times the upper limit of normal [ULN] on two consecutive weekly measurements) occurred in 0.2%, 1.5%, and 2.7% of patients treated with daily doses of 20, 40, and 80 mg (titrated to 40 mg twice daily) LESCOL capsules, respectively. Ninety-one percent of the cases of persistent liver function test abnormalities (20 of 22 patients) occurred within 12 weeks of therapy and in all patients with persistent liver function test abnormalities there was an abnormal liver function test present at baseline or by Week 8.

In the pooled analysis of the 24-week controlled trials, persistent transaminase elevation occurred in 1.9%, 1.8% and 4.9% of patients treated with LESCOL XL 80 mg, LESCOL 40 mg and LESCOL 40 mg twice daily, respectively. In 13 of 16 patients treated with LESCOL XL the abnormality occurred within 12 weeks of initiation of treatment with LESCOL XL 80 mg.

It is recommended that liver enzyme tests be performed prior to the initiation of LESCOL/LESCOL XL, and if signs or symptoms of liver injury occur.

There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including fluvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with LESCOL/LESCOL XL, promptly interrupt therapy. If an alternate etiology is not found do not restart LESCOL/LESCOL XL.

In very rare cases, possibly drug-related hepatitis was observed that resolved upon discontinuation of treatment. Active liver disease or unexplained serum transaminase elevations are contraindications to the use of LESCOL and LESCOL XL [ ]. Caution should be exercised when LESCOL is administered to patients with a history of liver disease or heavy alcohol ingestion [ ]. Such patients should be closely monitored. 1see Contraindications (4) and Warnings and Precautions (5.2)see Clinical Pharmacology (12.3)
Subjects in the Control arm will be observed between implant and month 12. During this time, the standard device diagnostic suite will be used as it would normally, in the office using the programmer, or by data transmission from the patient's home (or another remote location). At month 12 through study close (month 18), study doctors for the all subjects will have access to the risk status.
Disclosed are apparatus and methods for efficiently and effectively manipulating spreadable materials. Such apparatus and methods may be incorporated for uses such as applying spreadable materials such as hair color, relaxers, wax, and the like to a surface such as a body surface or the surface of strands of hair. A variety of applicators including varying edges, surfaces, tapers, and dimensions are disclosed, wherein each applicator configuration creates a different effect when used for hair processing. A user may select one or more of the disclosed applicators based upon the applicator's intended use, the ease of use of the particular applicator, and/or the user's personal preference. The applicators disclosed herein retain their rigidity during use, are fast-drying, create less waste, and are easy to clean. In one embodiment, a user may tailor the applicator's head design to meet his or her personal needs.
Studies of recent years prove that one of the important causes of metabolic disorders in people is a disturbed daily cycle, which is significantly influenced by the time of eating. It has been shown that more than 50% of the examined persons consumed food for 15 hours and more during the day. Limiting food consumption to 8-10 hours, without the need to reduce food intake, the so-called time-restricted eating (TRE), resulted in a significant improvement in metabolism, decrease in body weight and cholesterol concentration, increase in insulin sensitivity and many others. A period of hunger is necessary for the body to regenerate cell structures and allows for the separation of opposing metabolic processes. This means that the period of hunger is necessary and its limitation by e.g. snacking can seriously disturb this series of processes in the human body. The results of the investigators preliminary research indicate that TRE increases the vitality of the examined persons and their desire for doing exercise. So far, there are no studies on older people, where the intervention would consist in the use of TRE and endurance training such as Nordic walking (NW). The aim of this project is to demonstrate the synergistic effect of TRE and NW training on health indicators for older women. The women will be divided into four groups, i.e. Control group (CG); time-restricted eating group (TRG) which will follow 12 weeks of TRE protocol; Nordic walking training group (NWT) which will follow 12 weeks of supervised Nordic walking training and Nordic walking training combined with a time-restricted eating group (NW-TRG). In addition, it is assumed to prove that among young men, TRE will improve adaptation to endurance training and improve the metabolism. The study will be divided into two groups: 1. a group undergoing endurance training and 2. a group combining endurance training with TRE. In all subject's changes in the metabolism of iron, tryptophan, vitamin D and lipids will be evaluated. Endocrine function of skeletal muscles, mental state and cognitive abilities of the subjects will also be examined. The investigators expect that the applied procedure of temporary restriction of food intake will be easy to apply and continue for much longer than the study period. In order to maintain this time window, test subjects will be asked to delay their breakfast and early dinner intake. In addition, it is expected that the improvement in wellbeing, vitality and a significant improvement in performance and biochemical indicators of health, especially in the NWT plus TRE group, will allow to better understand the physiology of exercise, which may result in future specific health recommendations for people of different ages.
PROBLEM TO BE SOLVED: To obtain an agent for enhancing bactericidal power which not only improves the bactericidal action of a bactericide having cationic static charge without detriment to the cleaning action of a surfactant but also can reduce the feeling of stickiness of the skin to improve the feeling in use by using a sugar alcohol and/or a saccharide as the acting ingredient. SOLUTION: A monosaccharide-, oligosaccharide-, or polysaccharide-based one is used as the sugar alcohol and/or a saccharide, and among amt. a 4C or higher one, esp. 5-12C one, is effective, esp. pref. examples being sugar alcohols such as xylitol, sorbitol, and mannitol and saccharides such as glucose and trehalose. This agent for enhancing bactericidal power is used pref. in a wt. of at least 10 times that of a bactericide having cationic static charge, in a wt. of 1-15% of the bactericidal compsn., and in a wt. of 0.5-5 times that of the surfactant.